Adc Therapeutics SA
Research Adc Therapeutics SA (ADCT) on Bullrun: market cap USD 220.47M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerADCT
- ExchangeNYSE
- CountrySwitzerland
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 220.47M
- Financial periodQ2 2026
- RevenueUSD 19.25M
- Net income-USD 16.57M
- Free cash flow-USD 11.81M
- Gross margin87.8%
Valuation Snapshot
latest market cap is USD 220.47M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 81.36M | -USD 142.60M | -USD 141.44M | 92.9% | -1.12 | USD 261.34M | USD 3.00M | -USD 185.83M |
| FY2024 | USD 70.84M | -USD 157.80M | -USD 124.70M | 91.6% | -1.62 | USD 250.87M | USD 0 | -USD 202.64M |
| FY2023 | USD 69.06M | -USD 240.10M | -USD 121.90M | 96.3% | -2.94 | USD 278.60M | USD 124.38M | -USD 148.25M |
| FY2022 | USD 74.91M | -USD 157.13M | -USD 139.00M | 95.6% | -2.01 | USD 326.44M | USD 117.38M | USD 79.45M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 220.47M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 443.89M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 196.73M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 133.87M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 308.13M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.55B | n/a | n/a | n/a |
About Adc Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Adc Therapeutics SA's market cap?
Adc Therapeutics SA's market capitalization is USD 220.47M.
What does Adc Therapeutics SA do?
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.